Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 180

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 8
Chunk 180
---
 States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ KPMG LLP 

We have served as the Company’s auditor since 2020. 

Boston, Massachusetts 

March 18, 2025  

 69

MiNK THERAPEUTICS, INC. AND SUBSIDIARIES 

CONSOLIDATED BALANCE SHEET 

    December 31,

    2024

    2023

    ASSETS

    Cash and cash equivalents
     
    $
    4,577,040

    $
    3,367,229

    Prepaid expenses

    246,600

    53,111

    Other current assets

    164,244

    177,964

    Total current assets

    4,987,884

    3,598,304

    Equipment, net of accumulated depreciation of $524,639 and $495,638 as of    December 31, 2024 and 2023, respectively

    732,929

    953,977

    Total assets
     
    $
    5,720,813

    $
    4,552,281

    LIABILITIES AND